Brief: Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design
01/05/2025 17:26
May 1 (Reuters) - Nexalin Technology Inc NXL.O: NEXALIN TECHNOLOGY INITIATES FDA Q-SUBMISSION PROCESS FOR GEN-2 SYNC FOLLOWING ENCOURAGING DATA AND PRELIMINARY FDA FEEDBACK NEXALIN TECHNOLOGY INC - Q-SUBMISSION TO FACILITATE DIALOGUE WITH FDA ON CLINICAL TRIAL DESIGN Source text: ID:nGNX1pt4Nv Further company coverage: NXL.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Nexalin Technology
See all newsBrief: Nexalin Technology Regains Compliance With Nasdaq Minimum Bid Price Requirement Nasdaq Hearings Panel Grants Request For Continued Listing
NASDAQ RESUMED AT 12:48 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:43 PM
NASDAQ RESUMED AT 10:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:24 AM